文献速递类风湿关节炎

类风湿关节炎与金黄色葡萄球菌菌血症后骨关节感染及死亡风险:一项全国性队列研究

Rheumatoid arthritis and risk of osteoarticular infection and death following Staphylococcus aureus bacteraemia: a nationwide cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

类风湿关节炎组90天骨关节感染累积发生率为23.1%,非类风湿关节炎组为12.5%(HR 1.93);两组90天全因死亡率相似(35.4% vs 33.9%,HR 1.04)。

要点

  • 类风湿关节炎患者发生金黄色葡萄球菌菌血症后90天骨关节感染风险约为非类风湿关节炎患者的2倍(HR 1.93)。
  • 类风湿关节炎合并骨科植入物者骨关节感染累积发生率为29.4%(HR 1.75)。
  • 当前使用肿瘤坏死因子抑制剂者骨关节感染累积发生率为41.9%(HR 2.27)。

核心结论

  • 金黄色葡萄球菌菌血症后,近四分之一类风湿关节炎患者发生骨关节感染,风险约为非类风湿关节炎患者的两倍。
  • 类风湿关节炎患者中,骨科植入物和当前使用肿瘤坏死因子抑制剂与骨关节感染风险约翻倍相关。
  • 类风湿关节炎与非类风湿关节炎患者均有三分之一在90天内死亡。
  • 作者认为这些发现鼓励对合并金黄色葡萄球菌菌血症的类风湿关节炎患者保持警惕,以避免骨关节感染的治疗延迟。

研究设计与样本

  • 通过包括风湿病注册DANBIO在内的全国登记处识别类风湿关节炎、金黄色葡萄球菌菌血症、合并症及类风湿关节炎相关特征(如骨科植入物和抗风湿治疗)。
  • 共纳入18274例金黄色葡萄球菌菌血症患者,其中367例患有类风湿关节炎。
  • 采用多变量Cox回归估计骨关节感染和死亡的累积发生率及校正风险比(HR)。

主要发现

  • 类风湿关节炎组90天骨关节感染累积发生率为23.1%(95%CI 18.8; 27.6),非类风湿关节炎组为12.5%(95%CI 12.1; 13.0),HR 1.93(95%CI 1.54; 2.41)。
  • 类风湿关节炎合并骨科植入物者骨关节感染累积发生率为29.4%(95%CI 22.9; 36.2),HR 1.75(95%CI 1.08; 2.85)。
  • 类风湿关节炎中当前使用肿瘤坏死因子抑制剂者骨关节感染累积发生率为41.9%(95%CI 27.0; 56.1),与非使用者相比HR 2.27(95%CI 1.29; 3.98)。
  • 类风湿关节炎组90天全因死亡率为35.4%(95%CI 30.6; 40.3),非类风湿关节炎组为33.9%(95%CI 33.2; 34.5),HR 1.04(95%CI 0.87; 1.24)。

临床怎么用

  • 作者认为这些发现鼓励对合并金黄色葡萄球菌菌血症的类风湿关节炎患者保持警惕,以避免骨关节感染的治疗延迟。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Osteoarticular infection (OAI) is a feared complication of Staphylococcus aureus bacteraemia (SAB) and is associated with poor outcomes. We aimed to explore the risk of OAI and death following SAB in patients with and without rheumatoid arthritis (RA) and to identify risk factors for OAI in patients with RA. METHODS: Danish nationwide cohort study of all patients with microbiologically verified first-time SAB between 2006-18. We identified RA, SAB, comorbidities, and RA-related characteristics (e.g. orthopaedic implants and antirheumatic treatment) in national registries including the rheumatology registry DANBIO. We estimated the cumulative incidence of OAI and death and adjusted hazard ratios (HRs, multivariate Cox regression). RESULTS: We identified 18 274 patients with SAB (n = 367 with RA). The 90-day cumulative incidence of OAI was 23.1% (95% CI 18.8; 27.6) for patients with RA and 12.5% (12.1; 13.0) for patients without RA (non-RA) [HR 1.93 (1.54; 2.41)]. For RA patients with orthopaedic implants cumulative incidence was 29.4% (22.9; 36.2) [HR 1.75 (1.08; 2.85)], and for current users of tumor necrosis factor inhibitors (TNFi) it was 41.9% (27.0; 56.1) [HR 2.27 (1.29; 3.98) compared with non-users]. All-cause 90-day mortality following SAB was similar in RA [35.4% (30.6; 40.3)] and non-RA [33.9% (33.2; 34.5), HR 1.04 (0.87; 1.24)]. CONCLUSION: Following SAB, almost one in four patients with RA contracted OAI corresponding to a doubled risk compared with non-RA. In RA, orthopaedic implants and current TNFi use were associated with approximately doubled OAI risk. One in three died within 90 days in both RA and non-RA. These findings encourage vigilance in RA patients with SAB to avoid treatment delay of OAI.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Dieperink SS, Nørgaard M, Mehnert F, et al. Rheumatoid arthritis and risk of osteoarticular infection and death following Staphylococcus aureus bacteraemia: a nationwide cohort study. Rheumatology (Oxford). 2024. PMID: 38460189. doi:10.1093/rheumatology/keae132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。